Thermo Fisher Scientific (TMO) Q4 2022 Earnings Call Transcript

Thermo Fisher Scientific (TMO 0.60%)
Q4 2022 Earnings Call
Feb 01, 2023, 8:30 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2022 fourth-quarter conference call. My name is Brika, and I will be your event specialist running today's call. [Operator instructions] I would like to introduce our moderator for the call, Mr. Rafael Tejada, vice president, investor relations.

Mr. Tejada, you may begin your call. 

Raf Tejada -- Vice President, Investor Relations

Good morning, and thank you for joining us. On the call with me today is Marc Casper, our chairman, president, and chief executive officer; and Stephen Williamson, senior vice president, and chief financial officer. Please note, this call is being webcast live and will be archived on the Investors section of our website, thermofisher.com, under the heading News and Events until February 17, 2023. A copy of the press release of our fourth quarter and full year 2022 earnings is available in the Investors section of our website under the heading Financials.

So before we begin, let me briefly cover our safe harbor statement. Various remarks that we may make about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the Investors section of our website under the heading Financials SEC filings. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our estimates change.

Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. Also, during this call, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in the press release of our fourth quarter and full year 2022 earnings and also in the Investors section of our website under the heading Financials. So with that, I'll now turn the call over to Marc. 

Marc Casper -- Chairman, President, and Chief Executive Officer

Thank you, Raf. Good morning, everyone, and thanks for joining us today for our fourth quarter call and a wrap-up of a truly exceptional year for Thermo Fisher Scientific. We delivered another quarter of outstanding results in Q4. And as I reflect on the year, three things stand out to me.

Our proven growth strategy continues to drive significant share gain. Our differentiated customer value proposition is further elevating our trusted partner status with our customers. And this, in combination with the power of our PPI business system, drove outstanding financial performance for the quarter and full year, exceeding our ambitious goals. Our ability to deliver these results in a year that included global supply chain disruptions, or war in Ukraine, COVID-19 lockdowns in China, and inflationary headwinds wouldn't be possible without the incredible dedication of our team around the world.

I'm very grateful for our team's great execution in effectively navigating dynamic times and enabling the success of our company and our customers. Thanks to our colleagues, our company delivers spectacular 2022, and I couldn't be more excited for 2023. I'll get into more of the details in my remarks later, but first, let me recap the financials. Starting with the quarter.

Our revenue grew 7% to $11.45 billion. Our adjusted operating income was $2.56 billion, and we delivered another quarter of strong adjusted EPS performance, achieving $5.40 per share. Turning to our results for the full year. We grew revenue by 15% to $44.92 billion in 2022.

Adjusted operating income was $10.99 billion, and adjusted EPS of $23.24 per share. Let me turn to our end markets. We continue to deliver excellent and differentiated performance in Q4. This was driven by a continuation of good market conditions and outstanding execution from our global team, resulting in meaningful share gain.

Let me now give you some color for the quarter and the year. Starting with our largest end market, pharma, and biotech, we continued to deliver impressive performance with growth in the low teens for the quarter and mid-teens for the full year. Our differentiated customer value proposition is further elevating our trusted partner status with our pharma and biotech customers. Throughout the year, we had broad-based strength across our businesses serving this end market, highlighted by our bioproduction, pharma services, chromatography, and mass spectrometry businesses, as well as the research and safety market channel.

In academic and government, we grew in the mid-single digits for both the quarter and for the full year. We delivered strong growth across a range of our businesses, including biosciences, electron microscopy, chromatography, and mass spectrometry, as well as in the restructured safety market channel. In industrial and applied, we grew in the low teens for the quarter and mid-teens for the full year. During the year, we delivered strong growth in our electron microscopy and chromatography, and mass spectrometry businesses.

And finally, in diagnostics and healthcare. In Q4, revenue was approximately 40% lower than the prior-year quarter and 25% lower than full year 2021. The team delivered good core business growth during the year led by our microbiology and transplant diagnostic businesses as well as our healthcare market channel. I'll now turn to our growth strategy, which is delivering differentiated performance and setting us up for an even brighter future.

As a reminder, our strategy consists of three products: developing high-impact innovative new products, leveraging our scale in high-growth and emerging markets, and delivering a unique value proposition to our customers. Starting with the first pillar. It was another terrific year of high-effect innovation as we launched outstanding new products across our businesses that strengthen our industry leadership by enabling our customers to break new ground in their important work. In chromatography and mass spectrometry, our innovations are accelerating our customers' research and unlocking deeper analytical insights.

In 2022, we extended our industry-leading Thermo Scientific Orbitrap portfolio, launching the Orbitrap Ascend Tribrid mass spectrometer, advanced proteomics, metabolomics, and cancer biomarker research. We also launched the Thermo Scientific TRACE 1600 Series Gas Chromatograph to advance analytical testing for food, environmental, industrial, and pharmaceutical applications. In electron microscopy, the new Thermo Scientific Glacios 2 Cryo-EM was launched during the fourth quarter. It will help our customers accelerate structure-based drug discovery for debilitating disorders such as Alzheimer's, Parkinson's, and Huntington's diseases, as well as research for cancer and gene mutations.

We also continue to build our genetic sciences capabilities to help our customers understand, diagnose, and treat disease. During the fourth quarter, our SeCore CDx HLA sequencing system was granted marketing authorization by the U.S. FDA for use as a companion diagnostic with a T cell receptive therapy for adults with ocular melanoma. This is a really nice example of how our specialty diagnostics business is benefiting from our capabilities in life sciences solutions.

In addition, we expanded our PCR test menu to leverage our incredibly large installed base of instruments and launched the TruMark Infectious Disease Research Panels for rapid detection and research of infectious disease pathogens. To wrap up the innovation highlights, we added to our cell and gene therapy offering, most recently launching the Gibco CTS DynaCellect Magnetic Separation System. Our solutions are helping customers advance their cell and gene therapy programs. So another spectacular year of innovation, and we have an exciting pipeline of launches in 2023 and beyond.

The second pillar of our growth strategy is leveraging our scale in high-growth and emerging markets to create a differentiated experience for our customers. We continue to strengthen our capabilities serving these markets during the year, and I'll highlight a recent example. In the quarter, we opened a new CGMP biologics and sterile manufacturing facility in Hangzhou, China, which provides integrated clinical and commercial drug substance and drug product capabilities to help customers in China and in the Asia Pacific region deliver patient therapies more quickly. Turning to the third pillar of our growth strategy.

We continue to enhance our customer value proposition by strengthening our capabilities. We've been executing on the significant investments we've made over the past couple of years. And throughout 2022, we brought new capacity and capabilities online for pharma services, bioproduction, and clinical research services. Most recently, during the fourth quarter, we opened a new state-of-the-art bioanalytical lab in Richmond, Virginia to support our clinical research business and the increasing demand for our laboratory services to accelerate drug development.

As always, our PPI business system enabled our success during the year. It's helping us to drive meaningful share gain, maximize the return on investments, meet our customers' needs, and successfully navigate a dynamic environment, including effectively addressing inflation and global supply chain challenges. PPI engages and empowers all of our colleagues to find a better way every day and enables outstanding execution. We continue to successfully execute our capital deployment strategy, which is a combination of strategic M&A and returning capital to our shareholders.

In 2022, we successfully integrated PPD, our clinical research business. For the full year, PPD delivered core organic growth in the high teens, generating over $7 billion in revenue and contributing over $2 to our adjusted earnings per share. The combination of a great first share performance and excellent progress on our synergy realization is delivering very strong returns for our shareholders that is well ahead of the deal model. From a customer lens, the acquisition has further elevated our trusted partner status as customers are realizing significant value and partnering with our team to advance a scientific idea to an approved medicine.

In 2022, we also returned $3.5 billion of capital to our shareholders through stock buybacks and dividends. And on the first business day of 2023, we completed the acquisition of The Binding Site a leading specialty diagnostics company. The Binding Site is an exciting addition and highly complementary to our specialty diagnostics business. Together, we'll be able to advance the diagnosis and management of patients afflicted with multiple myeloma and immune disorders.

Reflecting on our progress of our ESG priorities in 2022, we further advanced our environmental and philanthropic efforts while also continuing to strengthen our company culture. During the year, we continued to advance our environmental sustainability roadmap, reducing our carbon emissions and finalizing significant power purchasing agreements to accelerate our transition toward a 100% renewable energy. Looking forward, we've also increased our 2030 greenhouse gas emissions reduction target to achieve a 50% reduction in this decade. Through our foundation for science, we continued to advance our philanthropic efforts and supported students across the globe during the year with our several education programs.

This included an announcement in the quarter for the Thermo Fisher Scientific Junior Innovators Challenge, the premier middle school STEM competition in the U.S. And throughout the year, Thermo Fisher Scientific was recognized for its industry leadership and inclusive culture. This includes earning 100% score on the Human Rights Campaign 2022 Corporate Equality Index for LGBTQ Equality for the seventh consecutive year as well as inclusion on Fortune's list of the world's most admired companies. In the quarter, we were recognized by Forest Magazine as one of the world's top female-friendly companies and one of America's best employers for veterans.

As I reflect on the year, I'm very proud of what our team accomplished. 2022 is a special year for Thermo Fisher, and I'm excited about 2023 and beyond. Stephen will outline the assumptions that factor into our revenue and earnings guidance, but let me quickly cover the highlights. We're initiating 2023 revenue guidance of $45.3 billion and adjusted EPS guidance of $23.70 per share.

This very strong financial outlook reflects a continuation of our track record of delivering excellent financial performance and sustainable value creation for all of our stakeholders. So I'll summarize our key takeaways for 2022. Our proven growth strategy continues to drive significant share gain. Our differentiated customer value proposition is further elevating our trusted partner status.

And this, in combination with the power of our PPI business system, drove outstanding financial performance for the quarter and full year, exceeding our ambitious goals while navigating a very dynamic macro environment. And we entered 2023 with strong momentum, and we're incredibly well-positioned beyond 2023. With that, I'll now hand the call over to our CFO, Stephen Williamson. Stephen? 

Stephen Williamson -- Senior Vice President, Chief Financial Officer

Thanks, Marc. And good morning, everyone. As you saw in our press release, in Q4, we delivered an outstanding quarter, capping off another excellent year. For the quarter and the full year, we delivered 14% core organic revenue growth.

This differentiated level of performance demonstrates the power of our growth strategy and the trusted partner status that we've earned with our customers. In addition, in Q4, we generated $370 million of COVID-19 testing revenue, $3.1 billion for the full year. Taking a step back and thinking about the top-line performance for the year, I'm really proud of what the team delivered. We offset $4.2 billion less testing revenue, which was a headwind of over 10%, and still delivered slightly positive organic growth for the year.

That's a great accomplishment. Then using the power of the PPI business system, we were able to translate the top-line strength to excellent adjusted EPS and cash flow results. In Q4, we delivered $0.23 more adjusted EPS than our prior guide, ending the year at $23.24 and delivered $6.94 billion of free cash flow, all while continuing to invest in the business to enable an even brighter future. So 2022 was another excellent year.

Let me now provide you with some details on our performance. Beginning with the earnings results. As I mentioned, we delivered $5.40 for adjusted EPS in Q4 and $23.24 for the full year. GAAP EPS in the quarter was $4.01 and $17.63 for the full year.

On the top line, as I mentioned in Q4, we delivered 14% core organic revenue growth of $370 million of testing revenue. Reported revenue grew 7% year-over-year. The components of our Q4 reported revenue increase included 3% lower organic revenue, a 14% contribution from acquisitions, and a headwind of 4% from foreign exchange. The full-year core organic revenue growth was 14%, and we delivered $3.1 billion in testing revenue.

For the full year 2022, reported revenue increased 15%. This includes slightly positive organic growth, and 18% contribution from acquisitions, and a 3% headwind from foreign exchange. Turn to our organic revenue performance by geography. The organic growth rate by region is skewed by the COVID-19 testing revenue in 2022 and the prior year.

In Q4, North America grew in the low single digits, Europe declined in the low teens, Asia Pacific in the mid-single digits, with China declining in the mid-single digits, and rest of the world declined high single digits. For the full year, North America grew in the low single digits; Europe declined high single digits; Asia Pacific grew high single digits, including China, which also grew high single digits for the year; and the rest of the world declined high single digits. On a core organic growth basis, all regions had strong growth in 2022. With respect to our operational performance, adjusted operating income in the quarter decreased 19%; and adjusted operating margin was 22.4%, 710 basis points lower than Q4 last year.

For the full year, adjusted operating income decreased 9%; and adjusted operating margin was 24.5%, which is 650 basis points lower than 2021. For both the fourth quarter and full year, we achieved strong price realization to effectively address inflation while also delivering strong productivity. This was more than offset by lower testing volumes, continued strategic investments, and the expected impact of incorporating PPD into our financials. For 2022, full-year adjusted operating margin was 40 basis points lower than assumed in the prior guidance.

Two-thirds of this was due to business and currency mix, and one-third due to onetime costs related to the runoff of testing revenue. Total company adjusted gross margin in the quarter came in at 41.4%, 910 basis points lower than Q4 last year. For the full year, adjusted gross margin was 43.5%, down 810 basis points versus the prior year. For both the fourth quarter and the full year, the change in gross margin was due to the same drivers as those of our adjusted operating margin.

Moving on to the details of the P&L. Adjusted SG&A in the quarter was 15.6% of revenue, an improvement of 170 basis points versus Q4 2021. For the full year, adjusted SG&A was 15.8% of revenue, an improvement of 130 basis points compared to 2021. Total R&D expense was $390 million in Q4.

For the full year, R&D expense was $1.5 billion, representing 5% growth over the prior year, reflecting our ongoing investments in high-impact innovation. R&D as a percent of our manufacturing revenue was 7% in Q4, 6.4% for the full year. Looking at our results below the line for the quarter. Our net interest expense was $119 million, which is $31 million favorable to Q4 last year.

Net interest expense for the full year was $454 million, a decrease of $39 million from 2021. Adjusted other income and expense was a net expense in the quarter of $10 million compared to net income of $7 million in Q4 2021. The year-over-year variance is primarily due to changes in nonoperating FX. For the full year, adjusted other income and expense was a net income of $14 million, which is $24 million lower than the prior year.

Our adjusted tax rate in the quarter was 12.8%, which is 100 basis points lower than Q4 last year, reflecting the results of our tax planning activities. For the full year, the adjusted tax rate was 13% or 160 basis points lower than 2021. We repurchased $1 billion of shares in Q4, bringing our total repurchases for 2022 to $3 billion. Average diluted shares were $393 million in Q4, approximately $4 million lower year-over-year, driven by share repurchases, net of option dilution.

Turning to cash flow and the balance sheet. Full year cash flow from continuing operations was $9.15 billion. Free cash flow for the year was $6.94 billion after investing $2.2 billion of net capital expenditures. We returned $118 million to shareholders through dividends in the quarter and $455 million for the full year.

We ended the quarter with $8.5 billion in cash and $34.5 billion of total debt. Our leverage ratio at the end of the quarter was 2.9 times gross debt to adjusted EBITDA and 2.2 times on a net debt basis. Concluding my comments on our total company performance, adjusted ROIC was 13.5%, reflecting the strong returns on investment that we're generating across the company. Now provide some color on the performance of our four business segments.

Let me start with a couple of framing comments. The scale and margin profile of our COVID-19 testing revenue varied by segment, and the testing revenue was significantly higher in the prior year, so that does skew some of the reported segment margins. We're executing strong pricing realization across all segments to address higher inflation. And we're referring to the acquired PPD business at our clinical research business, and that revised in laboratory products and biopharma services segment.

The anniversary date of the acquisition was December 8. Moving on to the segment details, starting with life sciences solutions. Q4 reported revenue in this segment declined 27%, and organic revenue was 24% lower than the prior year quarter. In Q4, we delivered very strong growth in our bioproduction business.

This was more than offset by the moderation in testing revenue in the segment versus the prior year quarter. For the full year, reported revenue in the segment declined 13%, and organic revenue declined 12%. Q4 adjusted operating income in life science solutions decreased 48%. And adjusted operating margin was 34.1%, down 14 percentage points versus the prior year quarter.

In Q4, we had unfavorable volume mix due to the significantly higher testing revenue in the prior year quarter. And for the full year, adjusted operating income decreased 29%. And adjusted operating margin was 41.2%, a decrease of 880 basis points versus 2021. In the analytical instruments segment, reported revenue increased 9% in Q4, and organic growth was 14%.

The strong growth in this segment this quarter was led by electron microscopy, and the chromatography, and mass spectrometry businesses. For the full year, reported revenue in the segment increased 9%, and organic revenue increased 14%. Q4 adjusted operating income in the segment increased 25%. And adjusted operating margin was 25.4%, up 330 basis points year-over-year.

In the quarter, we delivered strong volume pull-through and productivity. This was partially offset by strategic investments. For the full year, adjusted operating income increased 26%. And adjusted operating margin was 22.8%, up 310 basis points versus 2021.

Turning to our specialty diagnostics segment. In Q4, reported revenue declined 23%, and organic revenue was 20% lower than the prior-year quarter. In Q4, we continue to see strong underlying growth in the core led by our healthcare market channel, and our transplant diagnostics, and microbiology businesses. This was offset by lower COVID-19 testing revenue versus the year-ago quarter.

For the full year, reported revenue in the segment decreased 16%, and organic revenue was 13% lower than 2021. Q4 adjusted operating income decreased 30% in the quarter. And adjusted operating margin was 18.6%, down 190 basis points versus Q4 2021. During the quarter, we delivered strong productivity, which was more than offset by the impact of lower testing volume.

For the full year, adjusted operating income decreased 20%. And adjusted operating margin was 21.5%, down 110 basis points versus 2021. And finally, in laboratory products and biopharma services segment, Q4 reported revenue increased 42%, organic growth was 11%, and the impact of acquisitions was 35%. During Q4, organic revenue growth in this segment was led by the pharma services business.

PPD, our clinical research business, continued to perform very well. And during the quarter, it delivered over 20% core organic revenue growth and contributed $1.9 billion of revenue to the segment. For the full year, reported revenue in the segment increased 51%, and organic revenue increased 10%. Q4 adjusted operating income in the segment increased 73%.

And adjusted operating margin was 14.1%, which is 260 basis points higher than Q4 2021. In the quarter, we drove favorable business mix and delivered strong productivity and volume pull-through. That was partially offset by strategic investments. For the full year, adjusted operating income increased 56%.

And adjusted operating margin was 12.8%, up 40 basis points versus 2021. Let me now turn to our 2023 guidance. As Marc outlined, we're starting the year with a very strong financial outlook, consisting of revenue guidance of $45.3 billion and adjusted EPS guidance of $23.70. Let me provide some details of the underlying assumptions, starting with revenue.

Our initial guidance for 2023 assumes 7% core organic revenue growth, $400 million in testing revenue, $250 million of revenue from acquisitions, and a tailwind of $100 million from FX. This all assumes a return to more normal market growth conditions in 2023 in the range of 4% to 6%. Within our core revenue, we expect $500 million of vaccines and therapies revenue in 2023. This is $1.2 billion less than 2022, a 3% impact on core organic growth.

Even with this headwind, we are expecting to deliver 7% core organic revenue growth in 2023, demonstrating the strength of our initial outlook, the agility with which we're managing the business, and the ongoing benefits of our growth strategy. Turning to profitability. In 2023, we're assuming an adjusted operating margin of 23.9%. This is 60 basis points lower than 2022, driven by two elements: a 40 basis points of core margin expansion and 100-basis-point headwind from the runoff of testing revenue.

The year-over-year margin change is consistent with the comments I made on the last earnings call and have described how to model the margin impact of the different elements of the year-over-year change in revenue. In 2023, with a pandemic-related testing revenue behind us, I thought this would be a good opportunity to take a step back and take a multiyear view on our meaningful margin expansion progression. Starting in 2019, pre-pandemic, excluding the impact of PPD, we're on track to expand operating margins 60 basis points a year on average through 2023, a 20-basis-point improvement over the four-year period. So great progress on margin expansion.

Turning to adjusted EPS. We expect to deliver $23.70 in 2023. This is a 2% year-over-year increase, consisting of a 10% headwind from testing, more than offset by a 12% increase, driven by the core business. We're actively managing the whole P&L to effectively deal with material runoff in testing, and vaccines, and therapies revenue, and still grow our adjusted earnings per share for the year.

This shows the strength of our growth strategy and the power of our PPI business system. Moving on to some more detailed assumptions behind the guide. With regards to FX in 2023, we're assuming it's a year-over-year tailwind of approximately $100 million of revenue or 0.2%; and $0.04 to adjusted EPS, also 0.2%. We're suing at the binding site acquisition will contribute approximately $250 million to our reported revenue growth and $0.07 to adjusted EPS in 2023.

Below the line, we expect net interest expense in 2023 to be approximately $480 million. That's approximately $25 million higher than 2022 and includes the funding for The Binding Site acquisition. We assume that the adjusted income tax rate will be 11% in 2023. The improvement from 2022 is driven by a tax planning initiative.

We're expecting net capital expenditures will be approximately $2 billion in 2023, and free cash flow is assumed to be $6.9 billion for the year. In terms of capital deployment, our guidance assumes $3 billion of share buybacks, which were already completed in January. We estimate the full-year average diluted share count to be approximately 388 million shares. We're assuming that we'll return approximately $540 million of capital to shareholders this year through dividends.

And as is our normal convention, our guidance does not assume any future acquisitions or divestitures. And finally, I wanted to touch on quarterly phasing for the year. Revenue, adjusted operating margin, and adjusted EPS are all expected to ramp up as we go through the year. This is due to several factors.

Core organic revenue growth is expected to increase as we go through the year, largely due to the comps related to vaccines and therapies, as well as the expected phasing of economic activity in China. The impact of the runoff in testing revenue is most pronounced in Q1, and the benefits of the offsetting cost actions are spread over the year. From a foreign exchange standpoint, while a slight tailwind for the year as a whole, in Q1, FX is expected to be a year-over-year headwind of approximately $200 million of revenue and $80 million of adjusted operating income. Below the line, net interest expense is expected to decrease during the year as we generate free cash flow and earn interest on that cash build.

Putting all this together, for Q1, we expect core organic revenue growth to be in the mid-single digits. Adjusted operating margin to be slightly lower than Q4 2022, and adjusted EPS to be just over 20% of the full year total. So to wrap up, we had an excellent 2022, and we're really well-positioned to continue to deliver differentiated performance for all our stakeholders in 2023. I look forward to updating you on our progress as we go through the year.

With that, I'll turn the call back over to Raf. 

Raf Tejada -- Vice President, Investor Relations

Thank you, Stephen. Operator, we're ready for the Q&A portion of the call. 

Questions & Answers:

Operator

[Operator instructions] The first question we have from the phone lines comes from Jack Meehan of Nephron Research.  Your line is now open.

Jack Meehan -- Nephron Research -- Analyst

Thank you. Good morning. I wanted to start with the clinical research PPD performance. So high teens for the year, that's well above what we're seeing from a pure group.

So a three-parter for you, Marc. What was your book-to-bill in 2022? Two, how are the revenue synergies tracking? And then three, can you talk about what sort of growth you're assuming for this business in 2023? 

Marc Casper -- Chairman, President, and Chief Executive Officer

Sure. So Jack, thanks for the question. Our clinical research group has performed incredibly well, a great first year as part of the company, exceeding our own high level of ambition for the business. Integration has gone smoothly, Customers really see the obvious fit with the company and really has driven very strong momentum.

And our colleagues are very excited about the combination. So as I think about the different elements of performance, the book-to-bill was very positive. Authorization were very strong in the quarter and the year. So we entered the year with very strong momentum in terms of the backlog that we have in the business and the authorizations.

The revenue synergies, the way I would think about it is in two phases. Because of the long cycle nature from a win to revenue, we've won extremely substantial revenue synergies that will show up in the financials in 2023 and beyond. We had a small amount of revenue that came into the numbers last year, but we're talking in the hundreds of millions of dollars of wins that we've achieved from an authorization standpoint, so extremely positive. And in terms of our thoughts about 2023, it will grow above the company's average of the 7% growth that we outlined in the core.

So a nice contributor to the success. And really, it's been a seamless integration for the team. I'm very grateful for that. 

Jack Meehan -- Nephron Research -- Analyst

Excellent. And then I wanted to ask about the COVID vaccines and therapeutics. So you're assuming $500 million for the year. My question is simple.

Just how core are your core sales? Would you ever consider changing this definition, just confidence in the handoff as it pertains to bioprocessing in 2023? 

Marc Casper -- Chairman, President, and Chief Executive Officer

Yeah. So, Jack, thanks for the question. But when I think about the $500 million, right, and when I look at that, that number is primarily related to our pharma services activity. It's around actually producing the active pharmaceutical ingredients for the therapies.

It's for the sterile fill-finish primarily for the vaccines and some of the therapies. So we have pretty good visibility to that number. So I feel good about that. We decided back, I guess 1.5 years ago or whatever the exact time frame we did, the definition of core was we invested in capacity.

And if you think about a sterile fill-finish line, as an example, can be used for a COVID vaccine. It can also be used for pretty much any other biologic and even some of the small molecules, right? And therefore, our view was we would transition that capacity over time, and we have been, and we will. The other aspect of core is that if you think about how strong our growth was last year, well above our own ambitions, even the 12% we had laid out at the end of the third quarter, we've already transitioned a meaningful amount of that revenue in terms of other activities. So we didn't contemplate at all about changing the definition of what success is.

We think 7% is the right number for us. That core is the right definition for us. We'll provide transparency during the year about the different components as we always do so that investors can understand how we're getting there. But I feel great about the outlook, and I'm very proud of what the team delivered last year. 

Jack Meehan -- Nephron Research -- Analyst

Excellent. Thank you. 

Operator

Thank you. We have the next question from Patrick Donnelly of Citi. Your line is now open. 

Patrick Donnelly -- Citi -- Analyst

Good morning, guys. Thanks for taking the questions. Marc, maybe one on the analytical instruments business, 14% growth for the year is obviously pretty impressive. You guys have seen elevated growth for a good stretch here.

It did step down a little bit against easier comps. So I just wanted to get more color, I guess, on what you're seeing on the demand side, how you're seeing order trends and bookings there, visibility into 2023. I know you've had this elevated backlog we've talked a lot about. It seems like some peers are expecting kind of a normalization or moderation in the second half as we work our way through the year.

So I want to get your perspective of what you're seeing there. 

Marc Casper -- Chairman, President, and Chief Executive Officer

Yeah. Patrick, thanks for the question. So when I think about the analytical insurance business, a really strong year, excellent execution. There's nothing different in Q4 than in Q3.

So I wouldn't read anything into that. When I look at what's driving it, last year, you saw good market conditions. Funding was clearly strong. I don't know if there was a little bit of pent-up demand from 2020, I don't know.

But the funding was clearly available. We did very well with our innovation, right? We stayed committed to innovation throughout the early phase of the pandemic, making sure we have robust pipelines. You saw that in the stream of launches in our chromatography, and mass spectrometry, and electron microscopy businesses. Those products have been well adopted.

We're clearly growing very well. And as you know, we've also built out a very strong presence in enabling the next generation of semiconductors, battery applications, the most advanced aspects of material science. It's a different market position than really anybody else has in the industry. And that's driving great growth, right? You can see it in our electron microscopy numbers.

I'm very proud of how the team has executed. So that's kind of the context of why the elevated growth. So as I think about bookings demand, very strong throughout the year. So we have good visibility to the first half.

It's when those most of those orders will ship. We would expect that the analytical insurance business will be a really nice contributor to our growth for the year, and I think it's reasonable to assume that the growth normalizes more in the second half. As an assumption, it's not that I see something different or something happening in the market conditions, but our visibility is typically six months. So at the end of the first quarter, we'll have good visibility into the third quarter, and we'll keep you posted.

But I think for modeling purpose, I think normalization in the second half is a good assumption. 

Patrick Donnelly -- Citi -- Analyst

OK. That's helpful. And then maybe one for Stephen on the margins. Gross margins seem to have rebased.

I would love just your perspective of what those look like in '23 first off. And then maybe just the additional areas of leverage kind of down the P&L coming out of COVID. You mentioned maybe some elevated strategic investments in '22. Obviously, we saw some things like onetime bonuses that are pretty clear.

But it would be helpful if you could just talk through the moving pieces, what areas of additional leverage you do have coming out of '22. Because again, the mix, obviously, as LPS becomes bigger, the margins should kind of be lower, but you guys are putting up a pretty good number. So just trying to figure out again a little bit of the moving pieces and areas of leverage you have when you think about that 23.9% for '23. 

Stephen Williamson -- Senior Vice President, Chief Financial Officer

Yeah. So Patrick, thanks for the question. So when I think about the margin profile going forward, is that 7% to 9% core organic growth, driving 40 to 50 basis points is the right way to think about that company. And the margin opportunity there, you got a little bit of -- that assumes a little bit of price benefit, good volume leverage that comes with that, and still investing in the business to maintain that top-line growth, and then a continuation of using PPIs.

It's kind of decomplex the company. But I think that margin profile still holds in terms of going from the 23.9% going forward post 2023, I think about the levers that we have. As you saw in this past year, we had a slightly different mix, a lot higher growth in certain parts of our business. And slightly, margins were slightly different in Q4 than we had in the prior guide.

But the revenue was significantly higher. And what really matters is operating income dollars that we're driving, and that's incredibly strong. And I think our margin profile and the mix holds into 2023. And then, therefore, that kind of 7% to 9% driving that 40 to 50 is a good way to model the company. 

Patrick Donnelly -- Citi -- Analyst

And then just gross margins for '23 if you have them. 

Stephen Williamson -- Senior Vice President, Chief Financial Officer

I don't really want to give guidance that every single element of the P&L is that we're trying to manage a complex company, but a similar margin profile to where we are right now is probably a good starting point. But it really depends on the mix and also changes in currency, and our job is to manage the whole thing and deliver great results. 

Patrick Donnelly -- Citi -- Analyst

Thanks. Very helpful. Thank you, guys.

Operator

Thank you. Our next question comes from Rachel Vatnsdal of J.P. Morgan. 

Rachel Vatnsdal -- JPMorgan Chase and Company -- Analyst

OK. Thanks, operator. So first up, just on China, China declined mid-single digits during 4Q, and you said that some of that was testing roll-off. We also talked about how China is part of the reason that that core growth is going to ramp throughout the year.

So can you just walk us through, what are you embedding for China growth for 1Q and then for total 2023? And then can you also just spend a minute talking about the underlying demand trends for China and how you plan for the reopening trade? 

Marc Casper -- Chairman, President, and Chief Executive Officer

Rachel, thanks for the question. So if I step at the highest level with China, right, historically, been our fastest-growing end market. We have a very strong position. Our enabling technologies are important to life sciences, and food safety, and the biologics industry in China, etc.

So good demand drivers long term, long historical perspective. When I think about last year, team delivered high single-digit growth for the year. When I think about the fourth quarter, you had very, very significant disruptions from the end of the COVID -- zero COVID policies, right? So you went from this period where I think at least we had no problem in navigating through the challenges of the lockdown policies. But when you have 50%, 60%, 70% of colleagues with COVID, that's obviously highly disruptive.

And so you saw the first half of the quarter was strong, and the second half of the quarter was weak. Our assumption for this year is that the zero COVID opening up the economy leads to a weaker first quarter, a strong rebound in the balance of the year. China will grow on our expectations in our guidance a little bit faster for the full year than our core growth. So that's how I would think about it.

So a really strong end market, including the disruption from Q1. I think the team's done actually -- I'm very impressed with how they've dealt with all of the complexities and keeping our colleagues safe. It's been a challenging period of time. 

Rachel Vatnsdal -- JPMorgan Chase and Company -- Analyst

Great. And then maybe just kind of digging deeper on Patrick's question around margins. So you did 22.4% adjusted op for 4Q. You guided to step down on that operating margin line during 1Q, but then hitting that 23.9-ish is for the year for 2023.

So can you just kind of bridge us through the math there on margins and how that gives you confidence in the back half of the year to be able to round out at just shy of 24%? 

Stephen Williamson -- Senior Vice President, Chief Financial Officer

Yeah. So, Rachel, thanks for the question. So when I think about the margin progression through the year, Q1, we got a very significant roll-up in highly profitable testing revenue. And the cost actions against that to enable a 40% pull-through for the year, it's a combination of cost actions and then the non-repeat of the certain onetime things that we were doing on compensation in the prior year.

Those things spread over the whole year. So you get a little bit of benefit in Q1 to offset part of that profitability, but more of that offset really coming in the following three quarters. So that's really the largest piece to it. FX is a headwind to margins in Q1, so that's a slight aspect to it.

And then the phasing of the China activity is another aspect of that, kind of lower level of activity in Q1 and then ramping up to a higher level of revenue in Q4. 

Rachel Vatnsdal -- JPMorgan Chase and Company -- Analyst

Helpful. And then maybe just squeezing one more in here on industrial and applied. You grew low teens in 4Q. So can you just give us a little bit more granularity on that performance during the quarter, if there's any pockets about pace strength or softness relative to your expectations? And then how are you thinking about that industrial/applied market for 2023 given the macro backdrop? And is there any conservatism there in the assumed guidance? Thanks.

Marc Casper -- Chairman, President, and Chief Executive Officer

Yeah. So industrial and applied was very strong in the quarter, low teens growth in the quarter. Really strong demand and shipments for chromatography, mass spectrometry, and electron microscopy business. So we didn't see any concerns.

Our assumption for the year is that it's going to grow at about the about the average rate growth for the full year. So that's what we're assuming in the guidance. 

Rachel Vatnsdal -- JPMorgan Chase and Company -- Analyst

Great. Thank you.

Marc Casper -- Chairman, President, and Chief Executive Officer

Thanks, Rachel.

Operator

Thank you. We now have Derik De Bruin of Bank of America. Please go ahead when you are ready. 

Derik De Bruin -- Bank of America Merrill Lynch -- Analyst

Hello, and good morning. Stephen, it's not to pick on the margin point, but I do want to sort of clarify something. I mean I -- looking at the 40 to 50 basis points of expansion, so let's say you do 100 million next couple of years. I mean at your Analyst Day in May, you talked about a 26%-ish adjusted operating margin, excluding the impact of capital deployment.

Our -- I mean can you sort of just walk us through sort of like how you're thinking about the 2025 outlook that you provided and sort of like general thoughts around that and there? Thanks.

Stephen Williamson -- Senior Vice President, Chief Financial Officer

Yeah, when I think about margin profile, it's in combination with revenue dollars. So our revenue dollars are materially higher than we incorporated into my long-term model and a combination of that. Plus first, the margin gets you to a very strong operating income dollars, and that's what's driving EPS. I'm -- so we're well-positioned with the long-term model.

Derik De Bruin -- Bank of America Merrill Lynch -- Analyst

That's my thought. I just wanted to clarify that as well. And then just one quick follow-up. I assume there's some residual COVID business in your PPD.

You talked about core growth being 20%. What is the headwind in the PCD business from leftover COVID going from '23 to -- from '22 to '23?

Marc Casper -- Chairman, President, and Chief Executive Officer

Yeah. There's some activity of studies that will roll off over multiple years in terms of required follow-on studies and activity there that the team as those studies come off, they just have moved to other areas of the therapeutic range. So that really has been done quite seamlessly. And as you know, with the business scaling the way it is, having a large capable team is a great way to be able to be ready to serve the next set of customer work.

So pretty straightforward. 

Derik De Bruin -- Bank of America Merrill Lynch -- Analyst

And if I also can I squeeze one more in. Capex sort of outlook as we go from '23, you've been adding a lot of facilities. Can you sort of talk about what you're thinking about '23, '24? 

Marc Casper -- Chairman, President, and Chief Executive Officer

So '23, as Stephen said, it's a couple of billion dollars, and we'll continue to -- it will kind of go down to a glide path back to that 3.5% -- 3% to 3.5% over time. So nothing has changed in that assumption. 

Derik De Bruin -- Bank of America Merrill Lynch -- Analyst

Great. Thank you.

Marc Casper -- Chairman, President, and Chief Executive Officer

Thanks, Derik.

Operator

Thank you. Our next question comes from Dan Brennan of Cowen. Your line is now open, Dan. 

Dan Brennan -- Cowen and Company -- Analyst

Great. Thank you. Maybe Marc, to kick it off, just I'm all in on Aaron Rodgers if the Jets can get them. That would be like a struggling company.

Getting you as a CEO would be a great deal, I think. So just one of my questions here. Maybe the first one, just obviously, there's a lot of concerns in the industry broadly on the near-term drag on revenue growth for biologic drug products given the inventory depletion that's ongoing in the industry. You've been pretty confident that for various reasons, Thermo is really not seeing this.

Just would be interested to get an update on kind of just on your thinking there and kind of what you're assuming in your outlook for 7% growth for your businesses, both on the consumable side and on the Patheon services side. 

Marc Casper -- Chairman, President, and Chief Executive Officer

Yeah. So in terms of football, hope springs eternal until the person out. In terms of the bioproduction business, what I would say is a few points. Obviously, not every single player has reported, but a couple of them have.

So we have a sense of how the industry did and what others have said. When I think about last year, our bioproduction business just crushed it again, right? It's just phenomenal performance, well above the rate of growth of our pharma and biotech customer set, and that's three years in a row of really very strong growth. Very proud of how the team has executed. When I think about 2023, against tougher comparisons, obviously, the growth will normalize a bit.

And I would expect that based on some of the COVID comparisons of the first half of 2022 that you'll see more normalization in the first half. Stronger in the second half is the pattern, but it's a good business with incredibly bright prospects. So from that perspective, I feel good about how the team is managing and what the -- what '23 will contribute, and what the long term is going to be fantastic. Pharma services business has had a very good year, very strong growth, has brought its capacity online very effectively, and winning a lot of new business.

We still have activity this year that's meaningful in the vaccine therapies for COVID. And then as those wind down at some point in time, it's hard to know what the longer-term visibility for that. That capacity just gets repurposed on the things. So we do that in an orderly fashion.

So that's how I think about it. But a really strong year and some really nice meaningful wins throughout 2022 that sets up the pharma services business a good year and this year as well. 

Dan Brennan -- Cowen and Company -- Analyst

Got it. And then maybe just as a follow-up, obviously, your business mix is a lot less cyclical today than it was back in the prior downturn. Just wondering, implicit in the 7% Rachel asked a question on industrial business. But just to what extent does your guide bake in some cushion for a potential slowdown that could unfold given weaker macro? 

Marc Casper -- Chairman, President, and Chief Executive Officer

Yeah. So what we assumed is normal market conditions, right? And if the way I would characterize, last year was above normal market conditions. So normal in my definition is market close 4% to 6%, right? We said that for a very, very long time. So that's what we're assuming for this year.

If it's materially different than that, meaning that if the market conditions look anything like they look last year, we're going to grow well above the core guidance. If the market conditions are meaningfully worse than what's assumed in normal market conditions, then we're going to grow lower than the fourth-quarter organic that we outlined. So nothing is dramatic about that, and we'll be super transparent. And all our investors will understand if the world is totally different than what it looks like on February 1.

What we know is that we're going to manage incredibly well. And so whatever the world throws at us, we'll come out with great short-term performance and a much stronger industry leader for the long term. And that's what's super cool about Thermo Fisher because it's our job to manage the dynamics, and do it great, and do a great job for our investors. So I'm excited for what the world here holds in 2023 and beyond. 

Dan Brennan -- Cowen and Company -- Analyst

Great. Thank you. 

Operator

Thank you, Dan. We now have Vijay Kumar of Evercore ISI. Please go ahead when you're ready. 

Vijay Kumar -- Evercore ISI -- Analyst

Hey, guys. Congrats on a really strong finish to the year, and thanks for taking my question. I had two parts. Maybe I'll ask them both upfront.

Marc, the first part for you on -- when I look at this guidance on base organic, excluding vaccine, I think the business did -- the business is assuming, perhaps, low double-digit organic here in fiscal '23. And that's coming off of perhaps a mid-teens comp. One is that math correct, the base business, excluding vaccine, double digits. And what is it assuming? I'm assuming -- I'm thinking biopharma has to go at least my teens to get to that 9% to 10%, and it seems pretty strong.

Do those numbers make sense? And Stephen, the second part for you. On margins here, what are you assuming for decremental margins on COVID, and margins, and FX? And did I hear you correctly on Q1 is starting at 22%? I just want to make sure I heard the numbers right. 

Marc Casper -- Chairman, President, and Chief Executive Officer

Sure. So in terms of the guidance in the 7% core, we did not do a lot of machinations about excluding this or that. I think from the math, the way you're doing it is that if you excluded the vaccines and therapies, it would imply that the growth was 9% or 10%. Somewhere in that range is about what the growth would be on that measure for which we're not using that particular measure.

Therefore, you can't sort of speculate on sort of all the dynamic. It's much better to just say relative to our grow pharma and biotech, we expect to grow above that, right, in terms of its contribution to the 7%. And we would assume that the industrial and applied would go around the 7% core, and the other two markets are a little bit below. So that's how you should think about the different dynamics. 

Stephen Williamson -- Senior Vice President, Chief Financial Officer

Vijay, in terms of the pull-through on the lower testing revenue, as I outlined on the last call, the assumption is approximately 40% in aggregate for the whole year, but that doesn't all -- that's not the same in every single quarter. But the offsetting cost actions against a very significant profitability pull-through, which is higher than that on a contribution margin basis, they're spread across each of the quarters, but the revenue drop is largely just in Q1. So that's why you have the margin profile that I outlined for Q1. And the indication I gave for Q1 margin profile at this point is slightly below what we had in the margin in Q4.

So the largest driver there is that large drop in very profitable testing and then the offset on the cost to get it to the 40% pull-through spreads throughout the year. Thanks, Vijay. 

Raf Tejada -- Vice President, Investor Relations

Operator. We have time for one more question.

Operator

Thank you. Our final question comes from the line of Dan Arias of Stifel. Please go ahead when you're ready.

Dan Arias -- Stifel Financial Corp. -- Analyst

Hey, good morning, guys. Thanks for getting me in here. Marc, maybe just one on bioprocess, bioproduction. I just wanted to ask whether you're seeing any differences in purchasing patterns in the way that inventories just appear as though they're being managed when you look at CDMOs versus the biopharmas themselves.

There has been some conversation around just time lines that look like they might materialize on destocking. So curious if you can just sort of help us with what may be taking place, given where you sit here. 

Marc Casper -- Chairman, President, and Chief Executive Officer

Yeah. Dan, that's sort of along the line with Brian's question, really not much to add, right, which is phenomenal 2022. We created a really challenging and exciting comparison. We get paid to create those comparisons, and we expect that would show up in a more normalized growth in the first half and a little bit stronger than that in the second half.

And I think there's much color between the different customer types or that would provide much more insight on it. 

Dan Arias -- Stifel Financial Corp. -- Analyst

OK. Thanks so much.

Marc Casper -- Chairman, President, and Chief Executive Officer

Well, so let me wrap it up here. Thanks, everyone, for participating in the call. With another strong year behind us, we're in a great position to achieve another excellent year in 2023. And as always, thank you for your support of Thermo Fisher Scientific, and we look forward to updating you during the course of the year as it progresses.

Thanks, everyone. 

Operator

[Operator signoff]

Duration: 0 minutes

Call participants:

Raf Tejada -- Vice President, Investor Relations

Marc Casper -- Chairman, President, and Chief Executive Officer

Stephen Williamson -- Senior Vice President, Chief Financial Officer

Jack Meehan -- Nephron Research -- Analyst

Patrick Donnelly -- Citi -- Analyst

Rachel Vatnsdal -- JPMorgan Chase and Company -- Analyst

Derik De Bruin -- Bank of America Merrill Lynch -- Analyst

Dan Brennan -- Cowen and Company -- Analyst

Vijay Kumar -- Evercore ISI -- Analyst

Dan Arias -- Stifel Financial Corp. -- Analyst

More TMO analysis

All earnings call transcripts